A Study to Investigate the Sequencing Strategy of Pirtobrutinib After Disease Progression on First-line Acalabrutinib Treatment for Adult Participants with Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Trial Identifier:	D8220R00065
Sponsor:	AstraZeneca
Collaborator:	Eli Lilly and Company
Start Date:	June 2025
Primary Completion Date:	July 2028
Study Completion Date:	July 2030
Condition:	CLL (Chronic Lymphocytic Leukemia)

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

No documents have been posted yet.

Stay informed about new Trial Results Summaries with our email notification service

Trial Locations

No locations posted.

Pharma Intelligence UK Limited is a company registered in England and Wales with company number 13787459 whose registered office is 3 More London Riverside, London SE1 2AQ.